Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery - Building chiral technology toolboxes

Chirality

Volumn 19, Issue 9, 2007, Pages 658-682

  Mcconnell, Oliver ^a   Bach II, Alvin ^a   Balibar, Carx ^a,d   Byrne, Neal ^a,c   Cai, Yanxuan ^a   Carter, Guy ^b   Chlenov, Michael ^a   Di, Li ^a   Fan, Kristi ^a   Goljer, Igor ^a   He, Yanan ^a   Herold, Don ^a   Kagan, Michael ^a   Kerns, Edward ^a   Koehn, Frank ^b   Kraml, Christina ^a,c   Marathias, Vasilios ^a   Marquez, Brian ^a   Mcdonald, Leonard ^b   Nogle, Lisa ^a   Petucci, Christopher ^a   Schlingmann, Gerhard ^b   Tawa, Gregory ^a   Tischler, Mark ^b   Williamson, R Thomas ^b,e   Sutherland, Alan ^b   Watts, William ^a   Young, Mairead ^b   Zhang, Mei Yi ^a   Zhang, Yingru ^a,f   Zhou, Dahui ^a   Ho, Douglas ^c   more..

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Roche Carolina   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

Asymmetric transformations using enzymes; Chiral salt resolution; Chiral separations; Chiral technology; Determination of absolute stereochemistry; Enantiomeric separations; Supercritical fluid chromatography; Vibrational circular dichroism

Indexed keywords

ASYMMETRIC SYNTHESIS; CHIRALITY; CIRCULAR DICHROISM; DRUG INDUSTRY; DRUG RESEARCH; ENANTIOMER; LIQUID CRYSTAL; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; SUPERCRITICAL FLUID CHROMATOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY; CIRCULAR DICHROISM; DRUG DESIGN; DRUG INDUSTRY; ELECTRONS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; MOLECULAR CONFORMATION; SALTS; STEREOISOMERISM; TECHNOLOGY, PHARMACEUTICAL;

EID: 34748857631     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20399     Document Type: Review

References (400)

1. Grayson I, Drauz K. New applications of chiral technologies in the fine chemicals industry. Chim Oggi 2002;20:15-19.
2. Vaidya N. Diastereomeric crystallization - the "classical" chiral technology. Innovat Pharma Technol 2001;1:82-85.
3. Hollingsworth R. Carbohydrate-based chiral technology: challenging the petrochemistry paradigm. Chem Eng 2001;108:66-99.
4. Blacker J. Recent developments in chiral technology. Innovat Pharma Technol 2001;1:77-81.
5. Hollingsworth R, Wang G. Optically-active three-carbon synthons: Another milestone in the creation of a general carbohydrate chiral technology platform. Chim Oggi 2000;18:40-42.
6. McCague R. A chiral technology service to match outsourcing trends, Part 1. Speciality Chem 1998;18:402-403.
7. McCague R. A chiral technology service to match outsourcing trends, Part 2. Speciality Chem 1998;18:440-441.
8. Hirohara H. Chiral technology using hydrolytic enzymes: feasibility and mechanism of enzyme action. Bio Industry 1999;16:27-33.
9. Richards A, McCague R. The impact of chiral technology on the pharmaceutical industry. Chem Ind 1997;11:422-425.
10. Dyer R. Splitting it 50:50 - racemization as a chiral technology. Speciality Chem 1997;17:50-54.
11. Fadnavis N. Developments in chiral technology, Part II. Chem Ind Dig 1995;8:79-84.
12. Divakar K, Ekkundi V. Developments in chiral technology, Part I. Chem Ind Dig 1995;8:65-77.
13. Sheldon R. Chirotechnology. New York: Marcel Dekker; 1993. 423 pp.
14. Joseph-McCarthy D, Thomas IVB, Belmarsh M, Moustakas D, Alvarez J. Pharmacophore-based molecular docking to account for ligand flexibility. Protein Struct Funct Genet 2003;51:172-188.
15. Joseph-McCarthy D, Alvarez J. Automated generation of MCSS-derived pharmacophoric site points for search multiconformation databases. Protein Struct Funct Genet 2003;51:189-202.
16. Jennings A, Tennant M. Discovery strategies in a biopharmaceutical startup: maximizing your chances of success using computational filters. Curr Pharma Des 2005;11:335-344.
17. Baringhaus K-H, Hessler G. Fast similarity searching and screening hit analysis. Drug Discov Today 2004;1:197-202.
18. Singh R, Ethayathulla A, Jabeen T, Sharma S, Kaur P, Singh T. Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: crystal structure of th ecomplex formed between phospholipase A2 and aspirin at 1.9 angstrom resolution. J Drug Target 2005;13:113-119.
19. Dahl S, Sylte I. Molecular modelling of drug targets: the past, the present and the future. Basic Clin Pharmacol Toxicol 2005;96:151-155.
20. Douguet D, Munier-Lehmann H, Labesse G, Pochet S. LEA3D: a computer-aided ligand design for structure-based drug design. J Med Chem 2005;48:2457-2468.
21. Marrero-Ponce Y, Castillo-Garit JA, Olazabal E, Serrano HS, Morales A, Castanedo N, Ibarra-Velarde F, Huesca-Guillen A, Jorge E, del Valle A, Torrens F, Castro EA. Tomocomd-Cardd, a novel approach for computer-aided "rational" drug design, Part I: theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds. J Comput-Aided Mol Des2004;18:615-634.
22. Marrero-Ponce Y, Castillo-Garit JA, Olazabal E, Serrano HS, Morales A, Castanedo N, Ibarra-Velarde F, Huesca-Guillen A, Sanchez AM, Torrens F, Castro EA. Atom, atom-type and total molecular linear indices as a promising approach for bioorganic and medicinal chemistry: theoretical and experimental assessment of a novel method for virtual screening and rational design of new lead anthelmintic. Bioorg Med Chem 2005;13:1005-20.
23. Keenan SM, Geyer JA, Welsh WJ, Prigge ST, Waters NC. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors. Comb Chem High Throughput Screen 2005;8:27-38.
24. Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 2005;12:23-49.
25. Pratt DJ, Endicott JA, Noble ME. The role of structure in kinase-targeted inhibitor design. Curr Opin Drug Discov Devel 2004;7:428-436.
26. Sims PA, Wong CF, McCammon JA. Charge optimization of the interface between protein kinases and their ligands. J Comput Chem 2004;25:1416-1429.
27. Geney R, Sun L, Pera P, Bernacki R, Xia X, Horowitz S, Simmerling C, Ojima I. Use of the tubulin bound paclitaxel conformation for structure-based rational drug. Chem Biol 2005;12:339-348.
28. Gonzalez HD, Bastida I, Castanedo N, Nasco O, Olazabal E, Morales A, Serrano H, Armas RRd. Simple stochastic fingerprints towards mathematical modelling in biology and medicine, Part 1: the treatment of coccidiosis. Bull Math Biol 2004;66:1285-1311.
29. Rajappa M, Sharma A, Saxena A. Bioinformatics and its implications in clinical medicine: a review. Int Med J 2004;11:125-129.
30. Hajduk PJ, Mendoza R, Petros AM, Huth JR, Bures M, Fesik SW, Martin YC. Ligand binding to domain-3 of human serum albumin: a chemometric analysis. J Comput-Aided Mol Des 2003;17(2-4):93-102.
31. van de Waterbeemd H. Chemometric methods used in drug discovery. In: van de Waterbeemd H, editor. Structure-property correlations in drug research. London: Academic Press; 1996. p 55-80.
32. Manganaro V, Paratore S, Alessi E, Coffa S, Cavallaro S. Adding semantics to gene expression profiles: new tools for drug discovery. Curr Med Chem 2005;12:1149-1160.
33. Buehler LK. Is genomics advancing drug discovery? Pharma Discov 2005;5:28-29.
34. Orth AP, Batalov S, Perrone M, Chanda SK. The promise of genomics to identify novel therapeutic targets. Expert Opin Ther Targets 2004;8:587-596.
35. Lavedan C, Birznieks G, Dressman M, McCullough K, Paczkowski R, Torres R, Wolfgang C, Polymeropoulos M. Translating the genome into individualized therapeutics. Drug Dev Res 2004;62:371-382.
36. Lui DT. Expression genomics and cancer drug development. Drug Dev Res 2004;62:295-302.
37. Shastry BS. Role of SNP/haplotype map in gene discovery and drug development: an overview. Drug Dev Res 2004;62:143-150.
38. Janzen W, Bernasconi P, Cheatham L, Mansky P, Popa-Burke I, Williams KP, Worley J, Hodge N. Optimizing the chemical genomics process. In: Darvas F, Guttman A, Dorman G, editors. Chemical genomics: Advances in drug discovery and functional genomics applications. New York: Marcel Dekker; 2004. p 59-100.
39. Chin K-V, Selevanayagam ZE, Vittal R, Yang CS, Kitta T, Kudoh K, Shih WC, Yong L, Wong YF, Cheung TH, Chung TKH. Appplication of expression genomics in drug development and genomic medicine. Drug Dev Res 2004;62:124-133.
40. Lundstrom K. Structural genomics of GPCRs. Trends Biotechnol 2005;23:103-108.
41. Sanchez-Martin M, Gonzalez-Herrero I, Sanchez-Garcia I. Cancer genetics and drug discovery in mice. Lett Drug Des Discov 2004;1:353-360.
42. Auerbach D, Arnoldo A, Bogdan B, Fetchko M, Stagljar I. Drug discovery using yeast as a model system: a functional genomic and proteomic view. Curr Proteomics 2005;2:1-13.
43. Bilello JA. The agony and ecstasy of "OMIC" technologies in drug development. Curr Mol Med 2005;5:39-52.
44. Wiger Y, Levanon EY, Gerber D. From genome to antivirals: SARS as a test tube. Drug Discov Today 2005;10:345-352.
45. Brunden K, Sherf B, Harrington J. The application of RAGE and GECKO in cell-based target discovery screens. Pharmacogenomics 2005;6:383-392.
46. Kramer R, Cohen D. Functional genomics to new drug targets. Nat Rev Drug Discov 2004;3:965-972.
47. Zehender H, Le Goff F, Lehmann N, Filipuzzi I, Mayr LM. SpeedScreen: the "missing link" between genomics and lead discovery. J Biomol Screen 2004;9:498-505.
48. Brazeau DA. Combining genome-wide and targeted gene expression profiling in drug discovery: microarrays and real-time PCR. Drug Discov Today 2004;9:838-845.
49. Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004;3:136-151.
50. Hey N, Ivanov I, Meier-Ewert S. Genomics and proteomics tools for compound mode-of-action studies in drug discovery. Pharmacogenomics 2004;5:395-404.
51. Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 2004;40:2623-2632.
52. Chen WG, White FM. Proteomic analysis of cellular signaling. Expert Rev Proteomics 2004;1:343-354.
53. Walgren JL, Thompson DC. Application of proteomic technologies in the drug development process. Toxicol Lett 2004;149(1-3):377-385.
54. Gottfries J, Sjogren M, Holmberg B, Rosengren L, Davidsson P, Blennow K. Proteomics for drug target discovery. Chemom Intell Lab Syst 2004;73:47-53.
55. Toledo-Sherman LM, DeSouza L, Hosfield CM, Liao L, Boutilier K, Taylor P, Climie S, McBroom-Cerajewski L, Moran MF. New targets for an old drug: a chemical proteomics approach to unraveling the molecular mechanism of action of methotrexate. Clin Proteomics 2004;1:45-67.
56. Stoughton RB, Friend SH. How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov 2005;4:345-350.
57. Hebl BM, Daub H, Keri G. Chemical kinomics. Methods Principles Med Chem 2004;22:167-190.
58. Haar E, Walters WP, Pazhanisamy S, Talsimi P, Pierce AC, Bemis GW, Salituro FG, Harbeson SL. Kinase chemogenomics: targeting the human kinome for target validation and drug discovery. Mini Rev Med Chem 2004;4:235-253.
59. Baringhaus K-H, Hessler G. A chemical genomics approach for ion channel modulators. Methods Principles Med Chem 2004;22:221-242.
60. Darvas F, Dorman G, Krajcsi P, Puskas LG, Kovari Z, Lorincz Z, Urge L. Recent advances in chemical genomics. Curr Med Chem 2004;11:3119-3145.
61. Brown ED, Wright GD. New targets and screening approaches in antimicrobial drug discovery. Chem Rev 2005;105:759-774.
62. Ryan TP, Watson DE, Berridge BR. Toxicology biomarkers in drug development. Delivering on the genomic promise. Pharma Discov 2004;4:22-28.
63. Triggle DJ. Drug development in the 21st century: Medicines, man and receptors. Med Chem Res 2004;13(3/4):238-248.
64. Comess KM, Schurdak ME. Affinity-based screening techniques for enhancing lead discovery. Curr Opin Drug Discov Dev 2004;7:411-416.
65. Wheeler TT, Hood KA. The mammalian innate immune system: potential targets for drug development. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:237-247.
66. Penny MA, McHale D. Pharmacogenomics and the drug discovery pipeline: when should it be implemented? Am J Pharmacogenomics 2005;5:53-62.
67. Harrigan GG, Brackett DJ, Boros LG. Medicinal chemistry, metabolic profiling and drug target discovery: a role for metabolic profiling in reverse pharmacology and chemical genetics. Mini Rev Med Chem 2005;5:13-20.
68. Griffin JL. The potential of metabonomics in drug safety and toxicology. Drug Discov Today Technol 2004;1:285-293.
69. Khandelwal P, Beyer CE, Lin Q, McGonigle P, Schechter LE, Bach AC II. Nanoprobe NMR spectroscopy and in vivo microdialysis: new analytical methods to study brain neurochemistry. J Neurosci Methods 2004;133(1/2):181-189.
70. Khandelwal P, Beyer CE, Lin Q, Schechter LE, Bach AC II. Studying rat brain neurochemistry using nanoprobe NMR spectroscopy: A metabonomics approach. Anal Chem 2004;76:4123-4127.
71. Parsons L, Orban J. Structural genomics and the metabolome: combining computational and NMR methods to identify target ligands. Curr Opin Drug Discov Dev 2004;7:62-68.
72. Verhoeckx KC, Bijlsma S, Jespersen S, Ramaker R, Verheij ER, Witkamp RF, van der Greef J, Rodenburg RJ. Characterization of antiinflammatory compounds using transcriptomics, proteomics, and metabolomics in combination with multivariate data analysis. Int Immunopharmacol 2004;4:1499-514.
73. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004;22:245-252.
74. Keun HC, Ebbels TM, Bollard ME, Beckonert O, Antti H, Holmes E, Lindon JC, Nicholson JK. Geometric trajectory analysis of metabolic responses to toxicity can define treatment specific profiles. Chem Res Toxicol 2004;17:579-587.
75. Bailey WJ, Ulrich R. Molecular profiling approaches for identifying novel biomarkers. Expert Opin Drug Saf 2004;3:137-151.
76. Burczynski ME, Oestreicher JL, Cahilly MJ, Mounts DP, Whitley MZ, Speicher LA, Trepicchio WL. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Curr Mol Med 2005;5:83-102.
77. Dougherty T, Miller P. Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic ear. IDrugs 2006;9:420-422.
78. Weiler HN, Rubin AE, Moshiri B, Ruediger W, Li W-J, Allen J, Nolfo J, Bertok A, Rosso VW. Development and commercialization of the MiniBlock synthesizer family: a historical case study. JALA 2005;10:59-71.
79. Fokas D, Yu L, Baldino CM. Strategies for the synthesis of novel indole alkaloid-based screening libraries for drug discovery. Mol Divers 2005;9(1-3):81-89.
80. Dallinger D, Kappe CO. Creating chemical diversity space by scaffold decoration of dihydropyrimidines. Pura Appl Chem 2005; 77: 155-161.
81. Weber A, von Roedern E, Stilz HU. SynCar: an approach to automated synthesis. J Comb Chem 2005;7:178-184.
82. Musonda CC, Chibale K. Application of combinatorial and parallel synthesis chemistry methodologies to antiparasitic drug discovery. Curr Med Chem 2004;11:2519-2533.
83. Laird ER, Blake JF. Structure-based generation of viable leads from small combinatorial libraries. Curr Opin Drug Discov Dev 2004;7:354-359.
84. Metcalf IIICA, Sawyer T. Src homology-2 domains and structure-based, small-molecule library approaches to drug discovery. In: Makriyannis A, Biegel D, editors. Drug discovery strategies and methods. New York: Marcel Dekker; 2004. p 23-59.
85. Lee H. Pharmaceutical applications of liquid chromatography coupled with mass spectrometry (LC/MS). J Liquid Chromatogr Relat Technol 2005;28(7/8):1161-1202.
86. Paulson JL. A stand-alone monitoring system for reliable unattended operation of a commercial preparative LC/MS purification system. JALA 2005;10:6-15.
87. Ventura M, Farrell W, Aurigemma C, Tivel K, Greig M, Wheatley J, Yanovsky A, Milgram KE, Dalesandro D, DeGuzman R, Tran P, Nguyen L, Chung L, Gron O, Koch CA. High-throughput preparative process utilizing three complementary chromatographic purification technologies. J Chromatogr A 2004;1036:7-13.
88. Bolanos B, Greig M, Ventura M, Farrell W, Aurigemma CM, Li H, Quenzer TL, Tivel K, Bylund JMR, Tran P, Pham C, Phillipson D. SFC/MS in drug discovery at Pfizer, La Jolla. Int J Mass Spectrom 2003;238:85-97.
89. Davis PW, Griffith MC. High throughput parallel LC/MS/ELSD of combinatorial libraries using the eight-channel LCT system with MUX technology. In: Kyranos JN, editor. High throughput analysis for early drug discovery. San Diego, CA Elsevier; 2004. p 113-123.
90. Delaney J, Julien LV, Kyranos JN, Salvatore C. Purity and quantity determination of parallel synthesis compound libraries. In: Kyranos JN, editor. High throughput analysis for early drug discovery. San Diego, CA: Elsevier; 2004. p 95-112.
91. Lee H, Sarko CR. Analysis of a combinatorial library synthesized using a split-and-pool Irori MicroKan method for development and production. In: Kyranos JN, editor. High throughput analysis for early drug discovery. San Diego, CA: Elsevier; 2004. p 37-56.
92. Kyranos JN, Lee H, Goetzinger WK, Li LYT. One-minute full-gradient HPLC/UV/ELSD/MS analysis to support high-throughput parallel synthesis. J Combinat Chem 2004;6:796-804.
93. Guttman A, Varoglu M, Khandurina J. Multidimensional separations in the pharmaceutical arena. Drug Discov Today 2004;9:136-144.
94. Chen JM, Jin G, Sung A, Levin JL. X-ray crystallography combined with parallel synthesis. Bioorg Med Chem Lett 2002;12:1195-1199.
95. Natt O, Frahm J. In vivo magnetic resonance imaging: insights into structure and function of the central nervous system. Meas Sci Technol 2005;16:R17-R36.
96. Villar HO, Yan J, Hansen MR. Using NMR for ligand discovery and optimization. Curr Opin Chem Biol 2004;8:387-391.
97. Hajduk PJ, Huth JR, Fesik SW. Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 2005;48:2518-2525.
98. Huth JR, Yu L, Collins I, Mack J, Mendoza R, Isaac B, Braddock DT, Muchmore SW, Comess KM, Fesik SW, Clore GM, Levens D, Hajduk PJ. NMR-driven discoery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter. J Med Chem 2004;47:4851-4857.
99. Zhang J, McCombie G, Guenat C, Knochenmuss R. FT-ICR mass spectrometry in the drug discovery process. Drug Discov Today 2005;10(9):635-642.
100. Siegel MM. Mass spectrometry based assays for drug screening in the early phases of drug discovery. Frontiers Med Chem 2004;1:273-292.
101. Truebenbach CS, Tong H, Huang N, Schnier PD, Siegel MM. High throughput flow injection analysis-mass spectrometry for combinatorial chemistry using electrospray ionization, atmospheric pressure chemical ionization and exact-mass Fourier transform mass spectrometry. In: Kyranos JN, editor. High throughput analysis for early drug discovery. San Diego, CA: Elsevier; 2004. p 73-93.
102. Tabei K, Feng X, Vankatesan A, Abe T, Hideki U, Mansour TS, Siegel MM. Mechanism of inactivation of β-lactamases by novel 6-methylidene penems elucidated using electrospray ionization mass spectrometry. J Med Chem 2004;47:3674-3688.
103. Kruppa G, Schnier PD, Tabei K, Van Orden S, Siegel MM. Multiple ion isolation applications in FT-ICR MS: exact-mass MSn internal calibration and purification/interrogation of protein-drug complexes. Anal Chem 2002;74:3877-3886.
104. Braunschweig T, Chung J-Y, Hewitt SM. Perspectives in tissue microarrays. Comb Chem High Throughput Screen 2004;7:575-585.
105. Heymann G, Werling H-O. A generally applicable, high-throughput screening-compatible assay to identify, evaluate, and optimize antimicrobial agents for drug therapy. J Biomol Screen 2004;9:578-587.
106. Zhang H-Z, Kasibhatla S, Wang Y, Herich J, Guastella J, Tseng B, Drewe J, Cai SX. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 2004;12:309-317.
107. Yadavalli VK, Pishko MV Biosensing in microfluidic channels using fluorescence polarization. Anal Chim Acta 2004;501:123-128.
108. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee W-C, Pontz T, Corbley MJ, Cheung H-K, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGF receptor kinase (T RI). Bioorg Med Chem Lett 2003;13:4355-4359.
109. Entzeroth M. Emerging trends in high-throughput screening. Curr Opin Pharmacol 2003;3:522-529.
110. Netzer R, Bischoff U, Ebneth A. HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr Opin Drug Discov Dev 2003;6:462-469.
111. Vaschetto M, Weissbrod T, Bodle D, Guener O. Enabling high-throughput discovery. Curr Opin Drug Discov Dev 2003;6:377-383.
112. Kimple R, Jones M, Shutes A, Yerxa B, Siderovski D, Willard F. Established and emerging fluroescence-based assays for G-protein function: heterotrimeric G-protein alpha subunits and regulator of G-protein signaling (RGS) proteins. Combinat Chem High Throughput Screen 2003;6:399-407.
113. Asmild M, Oswald N, Kryzwkowski K, Friis S, Jacobsen R, Reuter D, boryski RT, Kutchinsky J, Vestergaard R, Schroder R, Sørensen CB, Bech M, Korsgaard MPG, Willumsen NJ. Upscaling and automation of electrophysiology: toward high throughput screening in ion channel drug discovery. Receptors Channels 2003;9:49-58.
114. Rychetsky P. Setting up a high-throughput screening operation for combichem libraries doesn't have to be a resource drain. PharmaChem 2002;1:2-5.
115. Kerns E, Di L. Automation in pharmaceutical profiling. JALA 2005;10:114-123.
116. Jenkins K, Angeles R, Quintos M, Xu R, Kassel D, Rourick R. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. J Pharma Biomed Anal 2004;34:989-1004.
117. Hersey A, Luscombe C, Modi S. In silico transporter modeling and its application in drug discovery. Biotechnol Pharma Aspects 2004;1:53-68.
118. Bemporad D, Luttmann C, Essex J. Computer simulation of small molecule permeation across a lipid bilayer: dependence on bilayer properties and solute volume, size, and cross-sectional area. Biophys J 2004;87:1-13.
119. El-Gendy A, Adejare A. Membrane permeability related physicochemical properties of a novel g-secretase inhibitor. Int J Pharma 2004;280(1/2):47-55.
120. Nassar A-E, Kamel A, Clarimont C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov Today 2004;9:1020-1028.
121. Hartmann T, Schmitt J. Lipophilicity - Beyond octanol/water: a short comparison of modern technologies. Drug Discov Today 2004;1:431-439.
122. Kerns E, Di L. Automated property profiling for cellular drug delivery. Cell Drug Deliv 2004:345-365.
123. Di L, Kerns E. Profiling drug-like properties in discovery research. Curr Opin Chem Biol 2003;7:402-408.
124. Kerns E. Pharmaceutical profiling in drug discovery. Drug Discov Today 2003;8:316-323.
125. Di L, Kerns E, Fan K, McConnell O, Carter G. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 2003;38:223-232.
126. Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003;11:391-406.
127. Veber D, Johnson S, Cheng H-Y, Smith B, Ward K, Kopple K. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615-2623.
128. Gao F, Johnson D, Ekins S, Janiszewski J, Kelly K, Meyer R, West M. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCP2D6, and CYP3A4 in vitro using a single point IC50. J Biomol Screen 2002;7:373-382.
129. Kerns E. High throughput physicochemical profiling for drug discovery. J Pharm Sci 2001;90:1838-1858.
130. Van de Waterbeemd H, Smith D, Beaumont K, Walker D. Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem 2001;44:1313-1333.
131. Bullock P. Alternate methods for assessing absorption, metabolism, and routes of elimnation. Drugs Pharma Sci 2005;152:303-347.
132. Li A. Preclinical in vitro screening assays for drug-like properties. Drug Discov Today 2005;2(2):179-185.
133. Di L, Kerns E. Application of pharmaceutical profiling assays for optimization of drug-like properties. Curr Opin Drug Discov Devel 2005;8:495-504.
134. Baringhaus K-H, Matter H. Efficient strategies for lead optimization by simultaneously addressing affinity, selectivity and pharmacokinetic parameters. In: Manhold R, Kubinyi H, Folkers G, editors. Methods and principles in medicinal chemistry, Vol. 23 (Chemoinformatics in drug discovery). Frankfurt: Wiley-VCH Verlag; 2005. p 1432-1436.
135. Takeda Y, Uoto K, Iwahana M, Jimbo T, Nagata M, Atsumi R, Onno C, Tanaka N, Terasawa H, Soga T. New highly active taxoids from 9b-dihydrobacctin-9.10- acetals, Part 5. Bioorg Med Chem Lett 2004;14:3209-3215.
136. Pinto D, Orwat M, Wang S, Fevig J, Quan M, Amparo E, Cacciola J, Rossi K, Alexander R, Smallwood A, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PYS. Discovery of 1-[3- (aminomethyl) phenyl]-N-3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl] -3-(trifluoromelhyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2001;44:566-578.
137. Fichert T, Yazdanian M, Proudfoot J. A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett 2003;13:719-722.
138. MacKenzie A, Marchington A, Middleton D, Newman S, Jones B. Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-2- piperidones, Part 1: Selective antagonists of the neurokinin-2 receptor. J Med Chem 2002;45:5365.
139. Hay M, Garnage S, Kovacs M, Pruijin F, Anderson R, Patterson A, Wilson W, Brown J, Denny W. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine J Med Chem 2003;46:169-182.
140. Peglion J-L, Goument B, Despaux N, Chariot V, Giraud H, Nisole C, Newman-Tancredi A, Dekeyne A, Bertrand M, Genissel P, Millan MJ. Improvement in the selectivity and metabolic stability of the serotonin 5-HT1A ligand, S 15535: a series of cis- and trans-2-(arycycloalkylamine) 1-indanols. J Med Chem 2002;45:165-176.
141. Hutchinson I, Jennings S, Vishnuvajjala B, Westwell A, Stevens M. Antitumor benzothiazoles, Part 16: Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J Med Chem 2002;45:744-747.
142. Liljebris C, Larsen S, Ogg D, Palazuk B, Bleasdale J. Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity. J Med Chem 2002;45:1785-1798.
143. Andersen H, Olsen O, Iversen L, Sorensen A, Mortensen S, Christensen M, Branner S, Hansen T, Lau J, Jeppesen L, Moran EJ, Su J, Bakir F, Judge L, Shahbaz M, Collins T, Vo T, Newman MJ, Ripka WC, Moller NP. Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. J Med Chem 2002;45:4443-4459.
144. Madsen P, Ling A, Plewe M, Sams C, Knudsen L, Sidelmann U, Ynddal L, Brfand C, Andersen B, Murphy D, Teng M, Truesdale L, Kiel D, May J, Kuki A, Shi S, Johnson MD, Testen KA, Feng J, Lakis J, Anderes K, Gregor V, Lau J. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J Med Chem 2002;45:5755-5775.
145. Al-awar R, Ray J, Schultz R, Andis S, Kennedy J, Moore R, Liang J, Golakoti T, Subbaraju G, Corbett T. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment A epoxides and chlorohydrins. J Med Chem 2003;46:2985-3007.
146. Chu-Moyer M, Ballinger W, Beebe D, Coutcher J, Day W, Li J, Oates P, Weekly R. SAR and species/stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470,711. Bioorg Med Chem Lett 2002;12:1477-1480.
147. Fichert T, Yazdanian M, Proudfoot J. A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett 2003;13:719-722.
148. Clark D. In silico prediction of blood-brain barrier permeation. Drug Discov Today 2003;8:927-933.
149. Singla A, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002;235:179-192.
150. Regueiro-Ren A, Leavitt K, Kim S-H, Hofle G, Kiffe M, Gougoutas J, DiMarco J, Lee F, Fairchild C, Long B, Vite GD. SAR and pH stability of cyanosubstituted epothilones. Org Lett 2002;4:3815-3818.
151. Fray M, Bull D, Carr C, Gautier E, Mowbray C, Stobie A. Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonist, Part 1: heterocyclic substituted 5-alkyl derivative. J Med Chem 2001;44:1951-1962.
152. Brooks G, Burgess W, Colthurst D, Hinks J, Hunt E, Pearson M, Shea B. Pleuromutilins, Part 1: the identification of novel mutilin 14-carbamates. Bioorg Med Chem 2001;9:1221-1231.
153. Goodwin JT, Conradi RA, Ho NFH, Burton PS. Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. J Med Chem 2001;44:3721-3729.
154. 1 receptor antagonist. J Med Chem 2001;44:2276-2285.
155. Brooks G, Burgess W, Colthurst D, Hinks JD, Hunt E, Pearson MJ, Shea B, Takle AK, Wilson AM, Woodnutt G. Pleuromutilins. Part 1: the identification of novel mutilin 14-carbamates. J Med Chem 2001;9:1221-1231.
156. Panchagnula R, Thomas N. Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm 2000;201:131-150.
157. Revesz L, Di Padova F, Buhl T, R F, Gram H, Hiestand P, Manning U, Zimmerlin A. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg Med Chem Lett 2000;10:1261-1265.
158. Bromidge S, Davies S, Duckworth D, Forbes I, Jones G, Jones J, King F, Blackburn T, Holland V, Kennett GA, Lightowler S, Middlemiss DN, Riley GJ, Trail B, Wood MD. 1-[2[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists. Bioorg Med Chem Lett 2000;10: 1867-1870.
159. Milbank J, Tercel M, Atwell G, Wilson W, Hogg A, Denny W. Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline(6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity. J Med Chem 1999;42:649-658.
160. Krise J, Zygmunt J, Georg G, Stella V. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodruges. J Med Chem 1999;42:3094-3100.
161. Patt WC, Cheng X-M, Repine JT, Lee C, Reisdorph BR, Massa MA, Doherty AM, Welch KM, Bryant JW, Flynn MA, Walker DM, Schroeder RL, Haleen SJ, Keiser JA. Butenolide endothelin antagonists with improved aqueous solubility. J Med Chem 1999;42:2162-2168.
162. Bulat S, Bosio S, Papadopoulos M, Cerezo-Galvez S, Grabowski E, Rosenbaum C, Matassa V, Ott I, Metz G, Schamberger J, Sekul R, Feurer A. Design and discovery of novel, potent pyrazinone-based thrombin inhibitors with a solubilizing amino P1-P2-linker. Lett Drug Des Discov 2006;3:289-292.
163. Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz III A, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL. Evolution of the thienopyridine class of inhibitors of IkB kinase-b, Part I: hit-to-lead strategies. J Med Chem 2006;49:2898-2908.
164. Barrett D, Catalano J, Deaton D, Hassell A, Long S, Miller A, Miller L, Ray J, Samano V, Shewchuk L, Wells-Knecht KJ, Willard Jr DH, Wright LL. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett 2006;16:1735-1739.
165. Castanedo G, Clark K, Wang S, Tsui V, Wong M, Nicholas J, Wickramasinghe D, Marsters J, Sutherlin D. DK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads. Bioorg Med Chem Lett 2006;16:1716-1720.
166. Goldstein D, Alfredson T, Bertrand J, Browner M, Clifford K, Dalrymple S, Dunn J, Freire-Moar J, Harris S, Labadie SS, La Fargue J, Lapierre JM, Larrabee S, Li F, Papp E, McWeeney D, Ramesha C, Roberts R, Rotstein D, San Pablo B, Sjogren EB, So O-Y, Talamas FX, Tao W, Trejo A, Villasenor A, Welch M, Welch T, Weller P, Whiteley PE, Young K, Zipfel S. S-[5-Amino-1-(4-fluorophenyl)-1H- pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy) phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 map kinase. J Med Chem 2006;49:1562-1575.
167. Stanton D, Mattioni B, Knittel J, Jurs P. Development and use of hydrophobic surface area (HSA) descriptors for computer-assisted quantitative structure-activity and structure-property relationship studies. J Chem Inf Comput Sci 2004;44:1010-1023.
168. Rouhi A. Chiral business. Chem Eng News 2003;81:45-55.
169. Rouhi A. Chiral roundup. Chem Eng News 2002;80:43-50.
170. Stinson C. Chiral pharmaceuticals. Chem Eng News 2001;79:79-97.
171. Stinson C. Chiral chemistry. Chem Eng News 2001;79:45-57.
172. Maier N, Franco P, Lindner W. Separation of enantiomers: Needs, challenges, perspectives. J Chromatogr A 2001;906:3-33.
173. Gerhard B. Synthesis of chiral drug substances. Synlett 2002;6:837-850.
174. Prentis R, Lis Y, Walder S. Pharmaceutical innovation by the seven U.K.-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1998;25:387-396.
175. Agranat I, Caner H, Caldwell J. Putting chirality to work: Strategy of chiral switches. J Nat Rev Drug Discov 2002;1:753-768.
176. Rouhi A. Chirality at work. Chem Eng News 2003;81:56-61.
177. Rouhi A. Chiral chemistry. Chem Eng News 2004;82:47-62.
178. Cheng X-M. To market, to market - 1993. Ann Rep Med Chem 1994;29:331-354.
179. Hegde S, Carter J. To market, to market - 2003. Ann Rep Med Chem 2003;39:337-368.
180. Hegde S, Schmidt M. To market, to market - 2004. Ann Rep Med Chem 2005;40:443-473.
181. Thayer A. Trial separations. Supercritical fluid chromatography gains favor in preparative-scale separations of enantiomers. Chem Eng News 2005;83:49-53.
182. Tucker G. Chiral switches. Lancet 2000;355:1085-1087.
183. Agranat I, Caner H. Intellectual property and chirality of drugs. Drug Discov Today 1999;4:313-321.
184. Anonymous. FDA's policy statement for the development of new stereoisomeric drugs, (corrections made on 1/3/97. More information on regulatory issues can be found at: http://www.fda.gov/cder/guidance/stereo.htm.) Chirality 1992;4:338-340.
185. Maas G. Determination of absolute and relative configuration by X-ray and neutron diffraction methods. In: Houben-Weyl, editor. Stuttgart: Thieme Verlag; 1996. p 399-497.
186. Stout G, Jensen L. X-ray structure determination: a practical guide, 2nd ed. New York: Wiley; 1989. 480 pp.
187. Schlingmann G, Roll D. Absolute stereochemistry of unusual biopolymers from Ascomycete culture LL-W1278: examples that derivatives of (S)-6-hydroxymellein are also natural fungal metabolites. Chirality 2005;17:S48-S51.
188. Charan R, Schlingmann G, Bernan V, Feng X, Carter G. Additional pyrrolomycins from cultures of Streptomyces fumanus. J Nat Prods 2005;68:277-279.
189. Berova N, Nakanishi K, Woody R. Circular dichroism: principles and applications. New York: Wiley-VCH; 2000. 878 pp.
190. Bari LD, Mannuccci S, Pescitelli G, Salvadori P. Assignment of absolute configuration of chiral carboxylic acids via exciton-coupled CD treatment: 4-phenylthioproline as a case study. Chirality 2002; 14: 611-617.
191. Meguro H, Kim J-H, Bai C, Nishida Y, Ohrui H. Some applications of a chiral fluorometric reagent, (S)-TBMB carboxylic acid. Chirality 2001;13:441-445.
192. Spodine E, Zolezi S, Calvo V, Decinti A. Studies of the circular dichroism spectra of dissymmetric Schiff-bases by means of the exciton chirality method. Tetrahedron: Asymmetry 2000;11:2277-2288.
193. Hartl M, Humpf H-U. 2-Naphthol as a powerful chromophore for the configurational assignment of carboxylic acid groups via the CD exciton chirality method. Tetrahedron: Asymmetry 2000;11:1741-1747.
194. Tanaka K, Pescitelli G, Di Bari L, Xiao TL, Nakanishi K, Armstrong D, Berova N. Absolute stereochemistry of dihydrofuroangeoicins bearing C-8 substituted double bonds: a combined chemical/exciton chirality protocol. Org Biomol Chem 2004;2:48-58.
195. Tanaka K, Pescitelli G, Nakanishi K, Berova N. Fluorescence detected exciton coupled circular dichroism: Development of new fluorescent reporter groups for structural studies. Monatshefte fuer Chemie 2005;136:367-395.
196. Tanaka K, Nakanishi K, Berova N. Absolute stereochemistry of allylic alcohols, amines, and other ene moieties: a microscale cross metathesis/exciton chirality protocol. J Am Chem Soc 2003;125:10802-10803.
197. Tanaka K, Itagaki Y, Satake M, Naoki H, Yasumoto T, Nakanishi K, Berova N. Three challenges toward the assignment of absolute configuration of gymnocin-B. J Am Chem Soc 2005;127:9561-9570.
198. Dale J, Dull D, Mosher H. α-Methoxy-α-trifluoromethylphenyl acetic acid, a versatile reagent for the determination of enantiomeric composition of alcohols and amines. J Org Chem 1969;34:2543-2549.
199. Trost B, Belletire J, Godleski S, McDougal P, Balkovec J, Baldwin J, Christy M, Ponticello G, Varga S, Springer JP. On the use of the O-methylmandelate ester for establishment of absolute configuration of secondary alcohols. J Org Chem 1986;51:2370-2374.
200. Ohtani I, Kusumi T, Kashman Y, Kakisawa H. A new aspect of the high-field NMR application of Mosher's method. The absolute configuration of marine triterpene sipholenol-A. J Org Chem 1991;56:1296-1298.
201. Seco J, Quinoa E, Riguera R. The assignment of absolute configuration by NMR. Chem Rev 2004;104:17-117.
202. Seco J, Quinoa E, Riguera R. A ppractical guide for the assignment of the absolute configuration of alcohols, amines and carboxylic acids by NMR. Tetrahedron: Asymmetry 2001;12:2915-2925.
203. Ohtani I, Kusumi T, Kashman Y, Kakisawa H. High-field FT NMR application of Mosher's method. The absolute configurations of marine terpenoids. J Am Chem Soc 1991;113:4092-4096.
204. Devlin F, Stephens P, Besse P. Are the absolute configurations of 2-(1-hydroxyethyl)-chromen-4-one and its 6-bromo derivative determined by X-ray crystallography correct? A vibrational circular dichroism study of their acetate derivatives. Tetrahedron: Asymmetry 2005;16:1557-1566.
205. Li J, Burgett A, Amezcua C, Harran P. Total synthesis of nominal diazonamides, Part 2: on the true structure and origin of the natural isolates. Angew Chem Int Ed Eng 2001;40:4770-4773.
206. Childers Jr W, Abou-Gharbia M, Kelly M, Andree T, Harrison B, Ho D, Hornby G, Huryn D, Potestio L, Rosenzweig-Lipson SJ, Schmid J, Smith DL, Sukoff SJ, Zhang G, Schechter LE. Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT1A antagonists: the discovery of Lecozotan. J Med Chem 2005;48:3467-3470.
207. Yamashita A, Norton E, Petersen P, Rasmussen B, Singh G, Yang Y, Mansour T, Ho D. Murayamycins, novel peptidoglycan biosynthesis inhibitors: synthesis and SAR of their analogues. Bioorg Med Chem Lett 2003;13:3345-3350.
208. Yamashita A, Norton E, Williamson R, Ho D, Sinishtaj S, Mansour T. Use of bis-(chiral-α-methylbenzyl)glycine esters for synthesis of enantiopure α-hydroxyamino esters. Org Lett 2003;5:3305-3308.
209. Sabb A, Stein R, Vogel R, Tasse R, Amburn S, Fairman D, Kowal D, Malhotra D, Boast C, Bartolomeo A, Morris H, Sailer T, Moyer JA, Abou-Gharbia M, Ho DM. WAY-131256 is an orally active, efficacious, and in vivo functionally selective M1 agonist. Drug Dev Res 1997;40:185-192.
210. Wang T, Shirota O, Nakanishi K, Berova N, McDonald L, Barbieri L, Carter G. Absolute stereochemistry of the spiroxins. Can J Chem 2001;79:1786-1791.
211. Guo J, Schlingmann G, Carter G, Nakanishi K, Berova N. Absolute stereochemistry of the strevertenes. J Chirality 2000;12:43-51.
212. Schlingmann G, Matile S, Berova N, Nakanishi K, Carter G. Absolute stereochemistry of the diepoxins. Tetrahedron 1996;52:435-446.
213. Lo L, Berova N, Nakanishi K, Schlingmann G, Carter G, Borders D. Determination of the absolute stereochemistry of nemadictine .alpha. 2 and .alpha. J Am Chem Soc 1991;114:7371-7374.
214. Francotte E. Enantioselective chromatography as a powerful alternative for the preparation of drug enantiomers. J Chromatogr A 2001;906:379-397.
215. Zhang Y, Wu D-R, Want-Iverson D, Tymiak A. Enantioselective chromatography in drug discovery. Drug Discov Today 2005;10:571-577.
216. Liu Y, Lantz A, Armstrong D. High efficiency liquid and super-subcritical fluid-based enantiomeric separations: an overview. J Liquid Chromatogr Relat Technol 2004;27(7-9):1121-1178.
217. Welch CJ, Leonard WR Jr, DaSilva J, Biba M, Albaneze-Walker J, Henderson D, Laing B, Mathre D. Preparative chiral SFC as a green technolog for rapid access to enantiopurity in pharmaceutical process research. LC-GC 2005;23:16-29.
218. Andersson ME, Asian D, Clarke A, Roeraade J, Hagman G. Evaluation of generic chiral liquid chromatography screens for pharmaceutical analysis. J Chromatogr A 2003;1005:83-101.
219. Andersson S, Allenmar S. Preparative chiral chromatographic resolution of enantiomers in drug discovery. J Biochem Biophys Methods 2002;54:11-23.
220. Zong-De Z, Yan-Ping S, Ting W. Development and validation of HPLC methods for enantioseparation of mirtazapine enantiomers at analytical and semipreparative scale using polysaccharide chiral stationary phases. Anal Chim Acta 2005;550(1/2):123-129.
221. Koppenhoefer B, Nothdurft A, Pierrot-Sanders J, Piras P, Popescu C, Roussel C, Stiebler M, Trettin U. CHIRBASE, a graphical molecular database on the separation of enantiomers by liquid-, supercritical fluid-, and gas chromatography. Chirality 1993;5:213-219.
222. Koppenhoefer B, Graf R, Holzschuh H, Nothdurft A, Trettin U, Piras P, Roussel C. CHIRBASE, a molecular database for the separation of enantiomers by chromatography. J Chromatogr A 1994;666(1/2):557-563.
223. Roussel C, Piras P, Heitmann I. An approach to discriminating 25 commercial chiral stationary phases from structural data sets extracted from a molecular database. Biomed Chromatogr 1997; 11:311.
224. Piras P, Roussel C, Pierrot-Sanders J. Reviewing mobile phases used on Chiralcel OD through an application of data mining tools to CHIRBASE database. J Chromatogr A 2001;906(1/2):443-458.
225. Roussel C, Pierrot-Sanders J, Heitmann I, Piras P. CHIRBASE: Database current status and derived research applications using molecular similarity, decision tree and 3D "enantiophore" search. In: Subramanian G, editor. Chiral separation techniques, 2nd ed. Weinheim, Germany: Wiley-VCH Verlag GmbH; 2001.
226. Del Rio A, Piras P, Roussel C. Enantiophore modeling in 3D-QSAR. A data mining application on Whelk-O1 chiral stationary phase. J Chirality 2006;18:498-508.
227. Navratilova H, Opatrilova R, Kriz Z, Koca J. Enantioselective chromatography and molecular modeling of novel aryloxyaminopropan-2-ols with the alkyl carbamate function. J Chirality 2004;16:139-146.
228. Del Rio A, Hayes J, Stein M, Piras P, Roussel C. Theoretical reassessment of Whelk-O1 as an enantioselective receptor for 1-(4-halogeno-phenyl)-1- ethylamine derivatives. Chirality 2004;16(Suppl):S1-S11.
229. Kafri R, Lancet D. Probability rule for chiral recognition. Chirality 2004;16:369-378.
230. Caetano S, Aires-de-Sousa J, Daszykowski M, Heyden Y. Prediction of enantioselectivity using chirality codes and classification and regression trees. Anal Chim Acta 2005;544:315-326.
231. de la Puente M, White C, Rivera-Sagredo A, Reilly J, Burton K, Harvey G. Impact of normal-phase gradient elution in chiral chromatography: a novel, robust, efficient and rapid chiral screening procedure. J Chromatogr A 2003;983:101-114.
232. Andersson M, Aslan D, Clarke A, Roeraade J, Hagman G. Evaluation of generic chiral liquid chromatography screens for pharmaceutical analysis. J Chromatogr A 2003;1005:83-101.
233. Petrin C, Vu VA, Matthijs N, Maftouh M, Massart DL, Heyden YV. Screening approach for chiral separation of pharmaceuticals, Part I: normal-phase liquid chromatography. J Chromatogr A 2002;947: 69-83.
234. Matthijs N, Perrin C, Maftouh M, Massart D, Heyden Y. Definition and system implementation of strategies for method development of chiral separations in normal-or reversed-phase liquid chromatography using polysaccharide-based stationary phases. J Chromatogr A 2004;1041:119-133.
235. Kellogg R, Nieuwenhuijzen J, Pouwer K, Vries T, Broxterman Q, Grimbergen R, Kaptein B, Crois FL, Wever Ed, Zwaagstra K, van der Laan AC. Dutch resolution: separation of enantiomers with families of resolving agents. A status report. Synthesis 2003;10:1626-1638.
236. Kaptein B, Vries T, Nieuwenhuijzen J, Kellogg R, Grimbergen R, Broxterman Q. Continuous developments in classical resolution: Dutch resolution and asymmetric transformation. Life Sciences-Advanced Synthesis & Catlysis. PharmaChem 2003;2:17-22.
237. Nieuwenhuijzen J, Grimbergen R, Koopman C, Kellogg R, Vries T, Pouwer K, van Echten E, Kaptein B, Hulshof L, Broxterman Q. The role of nucleation inhibition in optical resolutions with families of resolving agents. Angew Chem Int Ed Engl 2002;41:4281-4286.
238. Kaptein B, Boesten W, De Lange B, Grimbergen R, Hulshof L, Vries T, Seerden J-P, Broxterman Q. Production of enantiopure compounds by crystallization-induced resolution. Chim Oggi 2002;20(3/4):77-82.
239. Kaptein B, Elsenber H, Grimbergen R, Broxterman Q, Hulshof L, Pouwer K, Vries T. Dutch resolution of racemic 4-hydroxy- and 4-fluorophenylglycine with mixtures of phenylglycine and (+)-10-camphorsulfonic acid. Tetrahedron: Asymmetry 2000;11:1343-1351.
240. Vries T, Wynberg H, van Echten E, Koek J, ten Hoeve W, Kellog R, Broxterman Q, Minnaard A, Kaptein B, van der Sluis S, Hulshof L, Kooistra J. The family approach to the resolution of racemates. Angew Chem Int Ed Engl 1998;37:2349-2354.
241. Lammerhofer M. Chiral separations by capillary electromigratoin techniques in nonaqueous media, Part I: enantioselective nonaqueous capillary electrophoresis. J Chromatogr A 2005;1068:3-30.
242. Lammerhofer M. Chiral separations by capillary electomigration techniques in nonaqueous media, Part II: enantioselective nonaqueous capillary electrochromatography. J Chromatogr A 2005;1068:31-57.
243. Kang J. Recent progress in enantiomeric separation by capillary electrochromatography. Electrophoresis 2002;23:4005-4021.
244. Scriba G. Selected fundamental aspects of chiral electromigration techniques and their application to pharmaceutical and biomedical analysis. J Pharm Biomed Anal 2002;27:373-399.
245. Enlund A, Andersson M, Hagman G. Improved quantification limits in chiral capillary electrochromatography by peak compression effects. J Chromatogr A 2004;1028:333-338.
246. Levkin P, Levkina A, Schurig V. Combining the enantioselectivities of L-valine diamide and permethylated β-cyclodextrin in one gas chromatographic chiral stationary phase. Anal Chem 2006;78:5143-5148.
247. Volker S. Contributions to the theory and practice of the chromatographic separation of enantiomers. Chirality 2005;17(Suppl):S205-S226.
248. Kasai H, Tsubuki M, Takahashi K, Shirao M, Matsumoto Y, Honda Y, Seyama Y. Separation of stereoisomers of several furan derivatives by capillary gas chromatography-mass spectrometry, supercritical fluid chromatography, and liquid chromatography using chiral stationary phases. J Chromatogr A 2002;977:125-134.
249. Schurig Y. Separation of enantiomers by gas chromatography. J Chromatogr A 2001;906:275-299.
250. Berger TA. Separation of polar solutes by packed column supercritical fluid chromatography. J Chromatogr A 1997;785:3-33.
251. Berger T, Fogleman K, Staats T, Bente P, Crocket I, Farrell W, Osonubu M. The development of a semi-preparatory scale supercritical-fluid Chromatograph for high-throughput purification of 'combichem' libraries. J Biochem Biophys Methods 2000;43:87-111.
252. Berger T, Smith J, Fogelman K, Kruluts K. Semipreparative chiral separations using supercritical fluid chromatography with stacked injections. Am Lab 2002;34:14-20.
253. Berger T. Analytical and semipreparative supercritical fluid chromatography in drug discovery. Drugs Pharma Sci 2004;138:497-538.
254. Cirilli R, Orlando V, Ferretti R, Luciana T, Silvestri R, De Martino G, La Torre F. Direct HPLC enantioseparation of chiral aptazepine derivatives on coated and immobilized polysaccharide-based chiral stationary phases. J Chirality 2006;18:621-632.
255. Ghanem A, Hoenen H, Aboul-enein H. Application and comparison of immobilized and coated amylose tris-(3,5-dimethylphenylcarbamate) chiral stationary phases for the enantioselective separation of β-blockers enantiomers by liquid chromatography. Talanta 2006;68:602-609.
256. Maftouh M, Granier-Loyaux C, Chavana E, Marini J, Pradines A, Heyden YV, Picard C. Screening approach for chiral separation of pharmaceuticals, Part III: supercritical fluid chromatography for analysis and purification in drug discovery. J Chromatogr A 2005;1088:67-81.
257. White C. Integration of supercritical fluid chromatography into drug discovery as a routine support tool, Part I: fast chiral screening and purification. J Chromatogr A 2005;1074:163-173.
258. Ye Y, Stringham R. The effect of acidic and basic additives on the enantioseparation of basic drugs using polysaccharide-based chiral stationary phases. J Chirality 2006;18:519-530.
259. Gyllenhaal O, Stefansson M. Reversal of elution order for profen acid enantiomers in packed-column SFC on chiralpak AD. Chirality 2005;17:257-265.
260. Roussel C, Vanthuyne N, Serradeil-Albalat M, Vallejos J-C. True or apparent reversal of elution order during chiral high-performance liquid chromatography monitored by a polarimetric detector under different mobile phase conditions. J Chromatogr A 2003;995:79-85.
261. Okamoto M. Reversal of elution order during the chiral separation in high performance liquid chromatography. J Pharma Biomed Anal 2002;27:401-401.
262. Xiao T, Zhang B, Lee J, Hui F, Armstrong D. Reversal of enantiomeric elution order on macrocyclic glycopeptide chiral stationary phases. J Liquid Chrom Relat Technol 2001;24:2673-2684.
263. Zhang Y, McConnell O. Simulated moving columns technique for chiral liquid chromatography. J Chromatogr A 2004;1028:227-238.
264. Rodrigues A, APais L. Design of SMB chiral separations using the concept of separation volume. Sep Sci Technol 2004;39:245-270.
265. Chin C, Wang N-H. Simulated moving bed equipment designs. Sep Purifie Rev 2004;33:77-155.
266. Biressi G, Rajendran A, Mazzotti M, Morbidelli M. The GC-SMB separation of the enantiomers of isoflurane. Sep Sci Technol 2002;37:2529-2543.
267. Imamoglu S. Simulated moving bed chromatography (SMB) for application in bioseparation. Adv Biochem Eng/Biotechnol 2002;76:211-231.
268. Huthmann E, Juza M. Modification of a commercial chiral stationary phase. Influences on enantiomer separations using simulated moving bed chromatography. J Chromatogr A 2001;908(1/2):185-200.
269. Ludemann-Hombbourger O, Bailly M, Micoud R. Design of a simulated moving bed: optimal particle size of the stationary phase. Sep Sci Technol 2000;35:1285-1305.
270. Juza M, Mazzotti M, Morbidelli M. Simulated moving-bed chromatography and its application to chirotechnology. Trends Biotechnol 2000;18:108-118.
271. Kuester E, BGerber G, Antia F. Enantioseparation of a chiral epoxide by simulated moving bed chromatography using Chiralcel-OD. Chromatographia 1995;40 (7/8):387-393.
272. Zhang Y, Watts W, Nogle L, McConnell O. Rapid method development for chiral separation in drug discovery using multi-column parallel screening and circular dichroism signal pooling. J Chromatogr A 2004;1049(1/2):75-84.
273. Kagan M. Normal-phase high-performance liquid chromatographic separations using ethoxynonafluorobutane as hexane alternative, Part I: nalytical and chiral applications. J Chromatogr A 2001;918:293-302.
274. Kagan M, Chlenov M, Kraml C. Normal-phase high-performance liquid chromatographic separations using ehtoxynonafluorobutane as hexane alternative, Part II: liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry applications with methanol gradients. J Chromatogr A 2004;1033(1/2):321-331.
275. Ding J, Desai M, Armstrong D. Evaluation of ethoxynonafluorobutane as a safe and environmentally friendly solvent for chiral normal-phase LC-atmospheric pressure chemical ionization/electrospray ionization-mass spectrometry. J Chromatogr A 2005;1076(1/2):34-43.
276. Kagan M, Chlenov M, Bach A, McConnell O. Mass-directed normal-phase preparative HPLC with atmospheric pressure chemical ionization detection. J Liquid Chrom Relat Technol 2004;27:1817-1834.
277. Kagan M, Chlenov M, Greenfield A, Ho D. Normal-phase chiral liquid chromatography-mass spectrometry of non-UV-active compounds: Applications for pharmaceutically relevant racemates. J Chromatogr A 2006;1120:82-88.
278. Cai Y, Kingery D, McConnell O, Bach IIIA. Advantages of atmospheric pressure photoionization mass spectrometry in support of drug discovery. Rapid Commun Mass Spectrom 2005;19:1717-1724.
279. Kraml C, Zhou D, Byrne N, McConnell O. Enhanced chromatographic resolution of amine enantiomers as carbobenzyloxy derivatives in high-performance liquid chromatography and supercritical fluid chromatography. J Chromatogr A 2005;1100:108-115.
280. Nogle L, Mann C, Watts W Jr, Zhang Y. Preparative separation and identification of derivatized b-methylphenylalanine enantiomers by chiral SFC, HPLC and NMR for development of new peptide ligand mimetics in drug discovery. J Pharm Biomed Anal 2006;40:901-909.
281. Krishna S. Developments and trends in enzyme catalysis in nonconventional media. Biotechnol Adv 2002;20(3/4):239-267.
282. Koeller K, Wong C-H. Enzymes for chemical synthesis. Nature 2001;409:232-240.
283. Klibanov A. Improving enzymes by using them in organic solvents. Nature 2001;409:241-246.
284. Thayer A. Enzymes at work. Chem Eng News 2006;84:15-25.
285. Vieira T, Ferraz H, Andrade L, Porto A. Highly enantioselective enzymatic resolution of cis-fused octalols mediated by Candida Antarctica lipase (Novozym 435). Tetrahedron: Asymmetry 2006;17:1990-1994.
286. Fransson A-B, Xu Y, Leijondahl K, Baeckvall J-E. Enzymatic resolution, desymmetrization, and dynamic kinetic asymmetric transformation of 1,3-cycloalkanediols. J Org Chem 2006;71:6309-6316.
287. Easwar S, Argade N. A facile synthesis and enzymatic resolution of naturally occurring remotely functionalized alkylmethylmaleic anhydrides from Aspergillus wentii: aspergillus acids A-D. Synthesis 2006;5:831-838.
288. Miyazawa T, Kaito E, Yukawa T, Murashima T, Yamada T. Enzymatic resolution of 2-aryloxy-1-propanols via lipase-catalyzed enantioselective acylation using acid anhydrides as acyl donors. J Mol Catal B Enzym 2005;37(1-6):63-67.
289. Garcia-Urdiales E, Rebolledo F, Gotor V. Enzymatic one-pot resolution of two nucleophiles: alcohol and amine. Tetrahedron: Asymmetry 2000;11:1459-1463.
290. Lou W-Y, Zong M-H. Efficient kinetic resolution of (R,S)-1-trimethyl- silylethanol via lipase-mediated enantioselective acylation in ionic liquids. Chirality 2006;18:814-821.
291. Bellur E, Boettcher D, Borascheuer U, Langer P. Enantioselective synthesis of 2-alkylidenetetrahydrofurans based on a cyclization/enzymatic resolution strategy. Tetrahedron: Asymmetry 2006;17:892-899.
292. Shaw S-Y, Chen Y-J, Ou J-J, Ho L. Enzymatic resolution of methyl DL-β-acetylthioisobutyrate and DL-β- acetylthioisobutyramide using a stereoselective esterase from Pseudomonas putida IFO12996. J Mol Catal B Enzym 2006;38(3-6):163-170.
293. Truppo M, Journet M, Shafiee A, Moore J. Optimization and scale-up of a lipase-catalyzed enzymatic resolution of an indole ester intermediate for a prostaglandin D2 (DP) receptor antagonist targeting allergic rhinitis. Org Process Res Dev 2006;10:592-598.
294. Xin J, Zhao Y, Zhao G, Zheng Y, Ma X, Xia C, Li S. Enzymatic resolution of (R,S)-Naproxen in water-saturated ionic liquid. Biocatal Biotransform 2005;23:353-361.
295. Di L, McConnell O, Kerns E, Sutherland A. Rapid, automated screening method for enzymatic transformations using a robotic system and supercritical fluid chromatography. J Chromatogr B 2004;809:231-235.
296. Huang X, Fujioka N, Pescitelli G, Koehn F, Williamson R, Nakanishi K, Berova N. Absolute configurational assignments of secondary amines by CD-sensitive dimeric zinc porphyrin host. J Am Chem Soc 2002;124:10320-10335.
297. Kurtan T, Nesnas N, Li Y-Q, Huang X, Nakanishi K, Berova N. Chiral recognition by CD-sensitive dimeric zinc porphyrin host, Part 1: chiroptical protocol for absolute configurational assignments of monoalcohols and primary monamines. J Am Chem Soc 2001;123: 5962-5973.
298. Kurtan T, Nesnas N, Koehn F, Li Y-Q, Nakanishi K, Berova N. Chiral recognition by CD-sensitive dimeric zinc porphyrin host. 2. Structural studies of host-guest with chiral alcohol and monamine conjugates. J Am Chem Soc 2001;123:5974-5982.
299. Huang T, Nakanishi K, Berova N. Porphyrins and metalloporphyrins: versatile circular dichroic reporter groups for structural studies. J Chirality 2000;12:237-255.
300. Freedman T, Cao X, Dukor R, Nafie L. Absolute configuration determination of chiral molecules in the solution state using vibrational circular dichroism. Chirality 2003;15:743-758.
301. Stephens P. Vibrational circular dichroism spectroscopy: a new tool for the stereochemical characterization of chiral molecules. Comput Med Chem Drug Discov 2004:699-725.
302. Polavarapu P, He J. Chiral analysis using mid-IR vibrational CD spectroscopy. Anal Chem 2004:61A-67A.
303. Kuppens T, Herrebout W, Van der Veken B, Corens D, De Groot A, Doyon J, Van Lommen G, Bultinck P. Elucidation of the absolute configuration of JNJ-27553292, a CCR2 receptor antagonist, by vibrational circular dichroism analysis of two precursors. Chirality 2006;18:609-620.
304. Freedman T, Cao X, Phillips L, Cheng P, Dalterio R, Shu Y-Z, Zhang H, Zhao N, Shukla R, Tymiak A, Gozo SK, Nafie LA, Gougoutas JZ. Determination of the absolute configuration and solution conformation of a novel disubstituted pyrrolidine acid a by vibrational circular dichroism. Chirality 2006; 18:746-753.
305. Morita H, Kodama T, Tanaka T. Chirality of camphor derivatives by density functional theory. Chirality 2006;18:783-789.
306. Giorgio E, Tanaka K, Ding W, Krishnamurthy G, Pitts K, Ellestad G, Rosini C, Berova N. Theoretical simulation of the electronic circular dichroism spectrum of calicheamicin. Bioorg Med Chem 2005;13:5072-5079.
307. Schuhly W, Crockett SL, Fabian WMF. Hyperolactone C: determination of its absolute configuration by comparison of experimental and calculated CD spectra. Chirality 2005;17:250-256.
308. Superchi S, Giogio E, Rosini C. Structural determinations by circular dichroism spectra analysis using coupled oscillator methods: an update of the applications of the DeVoe polarizability model. Chirality 2004;16:422-451.
309. Polavarapu P. Protocols for the analysis of theoretical optical rotations. Chirality 2006;18:348-356.
310. Polavarapu P, Petrovic A, Wang F. Intrinsic rotation and molecular structure. Chirality 2003;15(Suppl):S143-S149.
311. Polavarapu P. Optical rotation: Recent advances in determining the absolute configuration. Chirality 2002;14:768-781.
312. Giorgio E, Roje M, Tanaka K, Hamersak Z, Sunjic V, Nakanishi K, Rosini C, Berova N. Determination of the absolute configuration of flexible molecules by ab initio ORD calculations: a case study with Cytoxazones and Isocytoxazones. J Org Chem 2005;70:6557-6563.
313. Stephens P, McCann D, Cheeseman J, Frisch F. Determination of absolute configurations of chiral molecules using ab inito time-dependent density functional theory calculations of optical rotation: how reliable are absolute configurations obtained for molecules with small rotations? Chirality 2005;17:S52-S64.
314. McCann D, Stephens P, Cheeseman J. Determination of absolute configuration using density functional theory calculation of optical rotation: chiral alkanes. J Org Chem 2004;69:8709-8717.
315. Stephens P, Devlin F, Cheeseman J, Frisch M, Bortoline O, Besse P. Determination of absolute configuration using ab initio calculation of optical rotation. Chirality 2003;15(Suppl):S57-S64.
316. Stephens P, Devlin F, Cheeseman J, Frisch F, Rosini C. Determination of absolute configuration using optical rotation calculated using density functional theory. Org Lett 2002;4:4595-4598.
317. Coriani S, Baranowska A, Ferrighi L, Forzato C, Marchesan D, Nitti P, Pitacco G, Rizzo A, Ruud K. Solvent effects on the conformational distribution and optical rotation of γ-methylparaconic acids and esters. Chirality 2006;18:357-369.
318. Specht K, Nam J, Ho D, Berova N, Kondru R, Beratan D, Wipf P, Pascal R Jr, Kahne D. Determining absolute configuration in flexible molecules: a case study. J Am Chem Soc 2001;123:8961-8966.
319. Freedman T, Cao X, Nafie L, Kalbermatter M, Linden A, Rippert A. Determination of the atropisomeric stability and solution conformation of asymmetrically substituted biphenyls by means of vibrational circular dichroism (VCD). Helvetic Chim Acta 2005;88:2302-2314.
320. Cichewicz R, Clifford L, Lassen P, Freedman XCT, Nafie L, Deschamps J, Kenyon V, Flanary J, Holman T, Crews P. Stereochemical determination and bioactivity assessment of (S)-(+)-curcuphenol dimers isolated from the marine sponge Didiscus aceratus and synthesized through laccase biocatalysis. Bioorg Med Chem 2005;13:5600-5612.
321. Freedman T, Cao X, Oliveira R, Cass Q, Nafie L. Determination of the absolute configuration and solution conformation of gossypol by vibrational circular dichroism. Chirality 2003;15:196-200.
322. Freedman T, Nafie XCL, Kalbermatter M, Linden A, Rippert A. An unexpected atropisomerically stable 1,1-biphenyl at ambient temperature in solution, elucidated by vibrational circular dichroism (VCD). Helvetica Chim Acta 2003;86:3141-3155.
323. Urbanova M, Setnicka V, Devlin F, Stephens P. Determination of molecular structure in solution using vibrational circular dichroism spectroscopy: the supramolecular tetramer of S-2,2′-dimethylbiphenyl-6,6′dicarboxylic acid. J Am Chem Soc 2005;127:6700-6711.
324. αα-disubstituted blycine with only axial chirality. Tetrahedron: Asymmetry 2003;14:1879-1893.
325. Dunmire D, Freedman T, Nafie L, Aeschlimann C, Gerber J, Gal J. Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroism. Chirality 2005;17:S101-S108.
326. Freedman T, Cao X, Nafie L, Solladie-Cavallo A, Jierry I, Bouerat L. VCD configuration of enantiopureAenriched tetrasubstituted α- fluorocyclohexanones and their use for epoxidation of trans-olefins. Chirality 2004;16:467-474.
327. Bour P, Navratilova H, Setnicka V, Urbanova M, Karel V (3R,4S)-4-(4-fluorophenyl)-3-hydroxymethyl-1-methylpiperidine: conformation and structure monitoring by vibrational circular dichroism. J Org Chem 2002;67:161-168.
328. Guo C, Shah R, Dukor R, Cao X, Freedman T, Nafie L. Determination of enantiomeric excess in samples of chiral molecules using Fourier transform vibrational circular dichroism spectroscopy: simulation of real-time reaction monitoring. Anal Chem 2004;76:6956-6966.
329. Maryanoff B, McComsey D, Dukor R, Nafie L, Freedman T, Cao X, Day V. Structural studies on McN-5652-X, a high-affinity ligand for the serotonin transporter in mammalian brain. Bioorg Med Chem 2003;11:2463-2470.
330. Guo C, Shah R, Mills J, Dukor R, Cao X, Freedman T, Nafie L. Fourier transform near-infrared vibrational circular dichroism used for on-line monitoring the epimerization of 2,2-dimethyl-1,3-dioxolane-4-methanol: A pseudo racemization reaction. Chirality 2006;18:775-782.
331. Monde K, Taniguchi T, Miura N, Vairappan C, Suzuki M. Absolute configurations of brominated sesquiterpenes determined by vibrational circular dichroism. Chirality 2006;18:335-339.
332. Vass E, Hollosi M, Forro E, Fulop F. VCD spectroscopic investigation of enantiopure cyclic β-lactams obtained through lipolase- catalyzedenantioselective ring-opening reaction. Chirality 2006;18:733-740.
333. He J, Wang F, Polavarapu P. Absolute configurations of chiral herbicides determined from vibrational circular dichroism. J Chirality 2005;17:S1-S8.
334. Devlin F, Stephens P, Bortolini O. Determination of absolute configuration using vibrational circular dichroism spectroscopy: phenyl glycidic acid derivatives obtained via asymmetric epoxidation using oxone and a keto bile acid. Tetrahedron: Asymmetry 2005;16:2653-2663.
335. Freedman T, Dukor R, Hoof Pv, Bach EK, Nafie L. Determination of the absolute configuration of (-)-mirtazapine by vibrational circular dichroim. Helvetica Chim Acta 2002;85:1160-1165.
336. Shah R, Nafie L. Spectroscopic methods for determining enantiomeric purity and absolute configuration in chiral pharmaceutical molecules. Curr Opin Drug Discov Dev 2001;4:764-775.
337. Petrovic A, He J, Polavarapu P, Xiao L, Armstrong D. Absolute configuration and predominant conformations of 1,1-dimethyl-2-phenyl-ethyl phenyl sulfoxide. Org Biomol Chem 2005;3:1977-1981.
338. Petrovic A, Polavarapu P, Drabowicz J, Zhang Y, McConnell O, Duddeck H. Absolute configuration of C2-symmetric spiroselenurane: 3,3,3′3′- tetramethyl-1,1'spriobi[3H. 2.1]benzoxaselenole. Chem Eur J 2005;11:4257-4262.
339. Stephens P, McCann D, Butkus E, Stoncius S, Cheeseman J, Frisch M. Determination of absolute configuration using concerted ab initio DFT calculations of electronic circular dichroism and optical rotation: bicyclo[3.3.1]nonane diones. J Org Chem 2004;69:1948-1958.
340. Stephens P, McCann D, Devlin F, Cheeseman J, Frisch M. Determination of the absolute configuration of [3.2](1,4)barrelenophanedicarbonnitrile using concerted time-dependent density functional theory calculations of optical rotation and electronic circular dichroism. J Am Chem Soc 2004;126:7514-7521.
341. Stephens P, McCann D, Devlin F, Flood T, Butkus E, Stoncius S, Cheeseman J. Determination of molecular structure using vibrational circular dichroism spectroscopy: the keto-lactone product of Baeyer-Villiger oxidation of (+)-(1R,5S)-bicyclo[3.3.1]nonane-2,7-dione. J Org Chem 2005;70:3903-3913.
342. Van Hink JW, Baek S-H, Barlow AJ, Ishii H, Nakanishi K, Berova N, Perry NB, Weavers RT. Determination of the absolute configuration of Anisotome irregular diterpenes: application of CD and NMR methods. Chirality 2004;16:549-558.
343. Vogensen SB, Greenwood JR, Varming AR, Brehm L, Pickering DS, Nielsen B, Liljefors T, Clausen RP, Johansen TN, Krogsgaard-Larsen P. A stereochemical anomaly: the cyclized (R)-AMPA analogue (R)-3-hydroxy-4,5,6,7- tetrahydroisoxazolo[5,4-c]pyridine-5-carboxylic acid [(R)-5-HPCA] resembles (S)-AMPA at glutamate receptors. Org Biomol Chem 2004;2:206-213.
344. Solladie-Cavallo A, Marsol C, Pescitelli G, DiBari L, Salvadori P, Huang X, Fujioka N, Berova N, Cao X, Freedman T, et al. (R)-(+)-and (S)-(-)-1-(9-phenanthryl)ethylamine: assignment of absolute configuration by CD tweezer and VCD methods, and difficulties encountered with the CD exciton chirality method. Eur J Org Chem 2002;11:1788-1796.
345. Lodine Monograph; 1993. 2581-2584 p.
346. Demerson C, Humber L, Dobson T, Jirkovsky I. Pyrano[3,4-b]- indolederivatives, pharmaceutical compositions and methods of use. US Patent No. 4,076,831, February 28, 1978.
347. Demerson C, Humber L, Phillip A. Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids. J Med Chem 1976;19:391-395.
348. Gonzalez A. A convenient preparation of 8-ethyl-4,9-dihydro-3H-pyrano[3, 4-b]indol-1-one, key intermediate of the antiinflammatory agent etodolac. Synth Commun 1991;21:669-674.
349. Humber L, Demerson C, Swaminathan P, Bird P. Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid): a potent antiinflammatory drug. Conformation and absolute configuration of its active enantiomer. J Med Chem 1986;29:871-874.
350. Brenna E, Fuganti C, Fuganti D, Grasseli P, Malpezzi L, Pedrocchi-Fantoni G. New enzymatic and chemical approaches to enantiopure etodolac. Tetrahedron 1997;53 (52):17769-17780.
351. Chou S-Y, Tseng C-L, Chang L-S. Exploration of an efficient method for optical resolution of etodolac. J Chin Chem Soc 2001;48:229-234.
352. Chou S-Y, Tseng C-L, Chen S-F. The formal synthesis of chiral etodolac using chiral 1,2-di(alkylcarbonyl)oxypentan-3-one as chiral building block. Heterocycles 1999;51:1527-1541.
353. Williamson R, Barrios Sosa A, Mitra A, Seaton P, Weibel D, Schroeder F, Meinwald J, Koehn F. New silyl ether reagents for the absolute stereochemical determination of secondary alcohols. Org Lett 2003;5:1745-1748.
354. Weibel D, Walker T, Schroeder F, Meinwald J. Chiral silylation reagents for the determination of absolute configuration by NMR spectroscopy. Org Lett 2000;2:2381-2383.
355. Seco J, Latypov S, Quinoa E, Riguera R. Determining factors in the assignment of the absolute configuration of alcohols by NMR. The use of anisotropic effects on remote positions. Tetrahedron 1997;53:8541-8564.
356. 1H NMR. J Org Chem 1996;61:8569-8577.
357. 19F-NMR analysis of mosher ester derivatives. J Am Chem Soc 1992;114:10203-10213.
358. Kelly D. A new method for the determination of the absolute stereo-chemistry of aromatic and heteraromatic alkanols using Mosher's esters. Tetrahedron: Asymmetry 1999;10:2927-2934.
359. 1H NMR: basis and applications. J Org Chem 2005;70:3778-3790.
360. Konno K, Fujishima T, Liu Z, Takayama H. Determination of absolute configuration of 1,3-diols by the modified Mosher's method using their di-MTPA esters. Chirality 2002;13:72-80.
361. Latypov S, Ferreiro M, Quinoa E, Riguera R. Assignment of the absolute configuration of β-chiral primary alcohols by NMR: scope and limitations. J Am Chem Soc 1998;120:4741-4751.
362. 1H NMR of 9-anthrylmethoxyacetates. Tetrahedron: Asymmetry 1996;7:2195-2198.
363. Rodriguez-Escrich S, Popa D, Jimeno C, Vidal-Ferran A, Pericas M. (S)-20[(R)-Fluoro(phenyl)methyl]oxirane: a general reagent for determining the ee of α-chiral amines. Org Lett 2005;7:3829-3832.
364. 1H NMR spectroscopy. J Org Chem 1999;64:4669-4675.
365. Seco J, Latypov S, Quinoa E, Riguera R. Choosing the right reagent for the determination of the absolute configuration of amines by NMR: MTPA or MPA? J Org Chem 1997;62:7569-7574.
366. 1H NMR of arylmethoxyacetic acid amides: the conformational model. J Org Chem 1995;60:1538-1545.
367. Trost B, Bunt R, Pulley S. On the use of O-methylmandelic acid for the establishment of absolute configuration of α-chiral primary amines. J Org Chem 1994;59:4202-4205.
368. Porto S, Duran J, Seco J, Quinoa E, Riguera R. "Mix and shake" method for configurational assignment by NMR: application to chiral amines and alcohols. Org Lett 2003;5:2979-2982.
369. Latypov S, Galiullina N, Aganov A, Kataev V, Riguera R. Determination of the absolute stereochemistry of alcohols and amines by NMR of the group directly linked to the chiral derivatizing reagent. Tetrahedron 2001;57:2231-2236.
370. Hoye T, Hamad A-S, DO K, MA T. An NMR method for determination of configuration of β-substituted carboxylic acids. Tetrahedron Lett 2000;41:2289-2293.
371. 1H NMR. Tetrahedron: Asymmetry 1997;8:1015-1018.
372. Hoye T, Koltun D. An NMR strategy for determination of configuration of remote stereogenic centers: 3-methylcarboxylic acids. J Am Chem Soc 1998;120:4638-4643.
373. Yang Y, Kayser M, Hooper D. Assignment of absolute configuration of 3-hydroxy β-lactams by the NMR "mix and shake" method. Chirality 2005;17:131-134.
374. 1H NMR anisotropy method. Chirality 2004;16:569-585.
375. 1H NMR anisotropy method. Chirality 2002;14:81-84.
376. Seco J, Tseng L-H, Godejohann M, Quinoa E, Riguera R. Simultaneous enantioresolution and assignment of absolute configuration of secondary alcohols by directly coupled HPLC-NMR of 9-AMA esters. Tetrahedron: Asymmetry 2002;13:2149-2153.
377. 1H NMR anisotropy method. Tetrahedron: Asymmetry 2000;11:1249-1253.
378. Cordero F, Pisaneschi F, Salvati M, Valenza S, Faggi C, Brandi A. Application of Mosher's method for absolute configuration assignment and resolution of 2-hydroxypyrrolizidinones. Chirality 2005;17:149-153.
379. Wentzel T, Wilcox J. Chiral reagents for the determination of enantiomeric excess and absolute configuration using NMR spectroscopy. Chirality 2003;15:256-270.
380. Lovely A, Wenzel T. Chiral NMR discrimination of pyrrolidines using (18-crown-6)-2,3,11,12-tetracarboxylic acid. Tetrahedron: Asymmetry 2006;17:2642-2648.
381. Kobayashi Y, Czechtizky W, Kishi Y. Complete stereochemistry of tetrafibricin. Org Lett 2003;5:93-96.
382. Kobayashi N, Hayashi N, Kishi Y. Toward the creation of NMR databases in chiral solvents: bidentate chiral NMR solvents for assignment of the absolute configuration of acyclic secondary alcohols. Org Lett 2002;4:411-414.
383. Kobayashi N, Hayashi M, Kishi Y. Application of chiral bidentate NMR solvente for assignment of the absolute configuration of alcohols: scope and limitation. Tetrahedron Lett 2003;44:7489-7491.
384. Kobayashi Y, Hayashi N, Kishi Y. Application of chiral bidentate NMR solvents for assignment of the absolute configuration of alcohols: Scope and limitation. Tetrahedron Lett 2003;44:7489-7491.
385. Emsley W, Lindon J. NMR spectroscopy using liquid crystal solvents. Oxford: Pergamon Press; 1975.
386. Farjon J, Merlet D, Philippe L, J C. Enantiomeric excess measurements in weakly oriented chiral liquid crystal solvents through 2D 1H selective refocusing experiments. J Magn Res 2002;158(1/2):169-172.
387. Parenty A, Campagne J-M, Aroulanda C, Lesot P. Routine use of natural abundance deuterium NMR in a polypeptide chiral oriented solvent for the determination of the enantiomeric composition of chiral building blocks. Org Lett 2002;4:1663-1666.
388. Sarfati M, Lesot P, Merlet D, Courtieu J. Theoretical and experimental aspects of enantiomeric differentiation using natural abundance multinuclear NMR spectroscopy in chiral polypeptide liquid crystals. Chem Commun 2000;21:2069-2081.
389. Canlet C, Merlet D, Lesot P, Meddour A, Lowewenstein A, Courtieu J. Deuterium NMR stereochemical analysis of threo-erythro isomers bearing remote stereogenic centers in racemic and non-racemic liquid crystalline solvents. Tetrahedron: Asymmetry 2000;11:1911-1918.
390. 19F-NMR spectroscopy in a chiral liquid crystal solvent. J Fluorine Chem 1997;86:149-153.
391. Meddour A, Berdague P, Hedli A, Courtieu J, Lesot P. Proton-decoupled carbon-13 NMR spectroscopy in a lyotropic chiral nematic solvent as an analytical tool for the measurement of the enantiomeric excess. J Am Chem Soc 1997;119:4502-4508.
392. Chevtchouk T, Ollivier J, Salaun J, Merlet D, Courtieu J. Determination of the regio- and enantioselectivity of the enzymatic hydrolyses of succinates based on H,C COLOC analysis and deuterium NMR in a chiral liquid crystal. Tetrahedron: Asymmetry 1997;8(7):999.
393. 3 chloride: A convenient nonchiral derivatizing agent for a facile enantiomeric excess determination of Amines through deuterium NMR. J Org Chem 1996;61:9035-9037.
394. 1H residual dipolar couplings in a chiral liquid crystal solvent using a natural abundance HSQC experiment. Magn Reson Chem 2005;43:512-519.
395. Thiele C, Berger S. Probing the diasterotopicity of methylene protons in strychnine using residual dipolar couplings. Org Lett 2003;5:705-708.
396. Thiele C. Poly-γ-ethyl-glutamate as alignment medium for the measurement of RDCs in organic substrates. J Org Chem 2004;69:7403-7413.
397. Verdier L, Sakhaii P, Zweckstetter M, Griesinger C. Measurement of long range H,C couplings in natural products in orientation media: a tool for structure elucidation of natural products. J Magn Res 2003;163:353-359.
398. Walsh R, Brander M, Fleischman S, Morales L, Moulton B, Rodriguez-Hornedo N, Zaworotko M. Crystal engineering of the composition of pharmaceutical phases. Chem Commun 2003:186.
399. 13C coupling observed via double quantum coherence. J Am Chem Soc 1980;102:4849-4851.
400. Clore G, Gronenborn A, Bax A. A robust method for determining the magnitude of the fully asymmetric alignment tensor of oriented macromolecules in the absence of structural information. J Magn Res 1998;133:216-221.